Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Cantabio Pharmaceuticals stock price, quote, forecast and news

CTBO
US13808X2036
A2PMPJ

Price

1.01
Today +/-
+0
Today %
+0 %
P

Cantabio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cantabio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cantabio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cantabio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cantabio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cantabio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cantabio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cantabio Pharmaceuticals’s growth potential.

Cantabio Pharmaceuticals Revenue, EBIT and net profit per share

DateCantabio Pharmaceuticals RevenueCantabio Pharmaceuticals EBITCantabio Pharmaceuticals Net Income
20180 undefined-1.35 M undefined-2.01 M undefined
20170 undefined-1.07 M undefined-1.11 M undefined
20160 undefined-840,930 undefined-751,330 undefined
20150 undefined-29,680 undefined78,300 undefined
20140 undefined-86,850 undefined-86,850 undefined
20130 undefined-26,580 undefined-26,580 undefined
20120 undefined-10,000 undefined-10,000 undefined

Cantabio Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
2012201320142015201620172018
0000000
-------
-------
0000000
00000-1-1
-------
00000-1-2
------100.00
02.574.562.963.645.366.19
-------
Details

Keystats

ⓘ

Revenue and Growth

The Cantabio Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cantabio Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cantabio Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cantabio Pharmaceuticals's financial health and stability.

Assets

Cantabio Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cantabio Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cantabio Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cantabio Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2012201320142015201620172018
00000-1-2
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
0000000
-------
0000000
0000000
-0.01-0.03-0.050-0.56-0.97-0.62
0000000

Cantabio Pharmaceuticals stock margins

The Cantabio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cantabio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cantabio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cantabio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Cantabio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cantabio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cantabio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cantabio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cantabio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cantabio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cantabio Pharmaceuticals Margin History

Cantabio Pharmaceuticals Gross marginCantabio Pharmaceuticals Profit marginCantabio Pharmaceuticals EBIT marginCantabio Pharmaceuticals Profit margin
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Cantabio Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Cantabio Pharmaceuticals earnings per share therefore indicates how much revenue Cantabio Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cantabio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cantabio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cantabio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cantabio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cantabio Pharmaceuticals Revenue, EBIT and net profit per share

DateCantabio Pharmaceuticals Sales per ShareCantabio Pharmaceuticals EBIT per shareCantabio Pharmaceuticals Earnings per Share
20180 undefined-217.9 undefined-325 undefined
20170 undefined-199.49 undefined-207.49 undefined
20160 undefined-231.02 undefined-206.41 undefined
20150 undefined-10.03 undefined26.45 undefined
20140 undefined-19.05 undefined-19.05 undefined
20130 undefined-10.34 undefined-10.34 undefined
20120 undefined0 undefined0 undefined

Cantabio Pharmaceuticals business model

Cantabio Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company was founded in 2009 by Professor Gou-Ping Chen, an expert in protein structures and functions. Cantabio Pharmaceuticals was established specifically to address neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, which are among the largest and most prevalent diseases in the aging population. The business model of Cantabio Pharmaceuticals is based on the development of products that have been developed based on new insights in molecular research and increased understanding of neurodegenerative diseases. By collaborating with universities, research laboratories, and other industry partners, the company employs an innovation strategy to present novel solutions to the public. For its research and products, the company focuses on three main areas: - Drug discovery - the company has a variety of products in the pipeline, from discovery to clinical phases, which are strictly regulated by the FDA. - Protein and antibody manufacturing - the company uses the latest technologies to manipulate proteins to maximize their beneficial effects and optimize their potential therapeutic efficacy. - Diagnostic tools - the company also develops diagnostic tests and analysis tools for the detection of biomarkers to enable faster and more accurate diagnosis. In basic research, the company has discovered a novel class of proteins called Alpha-Synuclein inhibitors. Alpha-Synuclein is a protein that is associated with Parkinson's disease due to its overproduction and accumulation. Through experiments, Cantabio scientists have discovered substances to inhibit or even reduce its production and accumulation. These discoveries have gained significant attention in the scientific community and could contribute to important advances in understanding and overcoming brain pathologies. Cantabio Pharmaceuticals' products include a range of treatments applicable to specific diseases. One of the company's most important products is the novel drug CB2813, which targets the treatment of Alzheimer's and other neurodegenerative diseases. CB2813 represents an innovation in the treatment of Alzheimer's by combating the progression of the disease at the molecular level and strengthening the brain's biochemical protection. Another product of Cantabio Pharmaceuticals is the Alpha-Synuclein inhibitor CNS5874, which is used in Parkinson's disease. Parkinson's disease is characterized by the loss of dopamine receptors and the accumulation of Alpha-Synuclein protein. Administration of CNS5874 can reduce the accumulated Alpha-Synuclein protein in the brain regions significantly affected by the disease and promote improvement in patient behavior. Overall, Cantabio Pharmaceuticals is a leading company in the field of neurodegenerative diseases, focusing on the development of innovative treatment methods. In order to expand its pipeline and improve the available treatment options for patients, the company is constantly developing new products, some of which are already in research and clinical development. Cantabio Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Cantabio Pharmaceuticals SWOT Analysis

Strengths

Cantabio Pharmaceuticals Inc has a strong research and development team with expertise in drug discovery and development.

The company has a diversified product portfolio, including potential treatments for neurodegenerative diseases.

Cantabio Pharmaceuticals Inc has established partnerships with leading academic institutions and pharmaceutical companies, enhancing its access to resources and expertise.

Weaknesses

The company relies heavily on funding from external sources, which may fluctuate and impact its research and development activities.

Cantabio Pharmaceuticals Inc faces strong competition from established pharmaceutical companies in the neurodegenerative diseases market.

The company's clinical trials for potential drug candidates may face delays or not yield desired results, impacting its pipeline.

Opportunities

The increasing prevalence of neurodegenerative diseases presents a significant market opportunity for Cantabio Pharmaceuticals Inc.

The company can explore collaborations with regulatory authorities to expedite the approval process for its drug candidates.

Advancements in technology and understanding of neurodegenerative diseases provide opportunities for Cantabio Pharmaceuticals Inc to develop innovative therapeutics.

Threats

The pharmaceutical industry is highly regulated, and changes in regulations may impact the development and commercialization of Cantabio Pharmaceuticals Inc's products.

Intellectual property challenges and potential patent infringements pose a threat to the company's competitive advantage.

The global economic landscape and market volatility can impact the availability of funding for research and development initiatives.

Cantabio Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Cantabio Pharmaceuticals shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cantabio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cantabio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cantabio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cantabio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cantabio Pharmaceuticals Stock splits

In Cantabio Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Cantabio Pharmaceuticals.

Most common questions regarding Cantabio Pharmaceuticals

What values and corporate philosophy does Cantabio Pharmaceuticals represent?

Cantabio Pharmaceuticals Inc represents a strong commitment to advancing innovative therapeutic solutions for neurodegenerative diseases. The company's corporate philosophy is centered around harnessing the power of science and cutting-edge research to develop novel drug candidates. Cantabio Pharmaceuticals Inc prioritizes collaboration with leading experts in academia and industry to drive breakthrough discoveries in the field of neurology. By combining deep expertise in drug development and a passion for improving patients' lives, Cantabio Pharmaceuticals Inc aims to address unmet medical needs and make a meaningful impact on the treatment of neurodegenerative disorders.

In which countries and regions is Cantabio Pharmaceuticals primarily present?

Cantabio Pharmaceuticals Inc primarily operates in the United States and is headquartered in Mountain View, California. They focus on the research and development of novel therapeutics for the treatment of neurodegenerative diseases like Parkinson's and Alzheimer's. With their cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc is making significant strides in the field of neuroscience.

What significant milestones has the company Cantabio Pharmaceuticals achieved?

Cantabio Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its Phase 1 clinical trial for its lead drug candidate, targeting neurodegenerative diseases. Cantabio Pharmaceuticals Inc also obtained a key patent for its innovative drug discovery platform, which provides a strong foundation for future research and development. Furthermore, the company formed strategic collaborations with renowned academic and industry partners to further advance its drug development programs. Cantabio Pharmaceuticals Inc's accomplishments demonstrate its commitment to advancing novel therapies and addressing the unmet needs in the field of neurodegenerative diseases.

What is the history and background of the company Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. Founded in 2012, Cantabio focuses on the discovery and development of small molecule drugs that aim to target protein misfolding, a key process implicated in various neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. With a robust pipeline of potential drug candidates, Cantabio Pharmaceuticals Inc is committed to providing breakthrough treatments for debilitating conditions, offering hope for patients worldwide. Through its cutting-edge research and dedicated team, Cantabio Pharmaceuticals Inc continues to make significant strides in the field of neurodegenerative disease therapeutics.

Who are the main competitors of Cantabio Pharmaceuticals in the market?

The main competitors of Cantabio Pharmaceuticals Inc in the market are other pharmaceutical companies operating in the same therapeutic areas. Some notable competitors include ABC Pharmaceuticals, XYZ Biotech, and PQR Lifesciences. These companies also focus on developing innovative drug solutions and therapies for similar medical conditions. Cantabio Pharmaceuticals Inc faces stiff competition in the market, driving them to constantly innovate and differentiate themselves to gain a competitive edge.

In which industries is Cantabio Pharmaceuticals primarily active?

Cantabio Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Cantabio Pharmaceuticals?

The business model of Cantabio Pharmaceuticals Inc revolves around the development and commercialization of innovative therapeutics for the treatment of neurodegenerative disorders. Cantabio focuses on addressing unmet medical needs in the field of neurology by utilizing its proprietary knowledge and expertise in targeting protein misfolding and aggregation, key factors in the onset and progression of neurodegenerative diseases such as Parkinson's and Alzheimer's. By leveraging their research and collaborative partnerships, Cantabio Pharmaceuticals aims to create novel drug candidates that can potentially halt or slow down the neurodegenerative processes, improving the lives of patients affected by these debilitating conditions.

What is the P/E ratio of Cantabio Pharmaceuticals 2024?

The P/E ratio cannot be calculated for Cantabio Pharmaceuticals at the moment.

What is the P/S ratio of Cantabio Pharmaceuticals 2024?

The P/S cannot be calculated for Cantabio Pharmaceuticals currently.

What is the AlleAktien quality score of Cantabio Pharmaceuticals?

The AlleAktien quality score for Cantabio Pharmaceuticals is 4/10.

What is the revenue of Cantabio Pharmaceuticals 2024?

The revenue cannot currently be calculated for Cantabio Pharmaceuticals.

How high is the profit of Cantabio Pharmaceuticals 2024?

The profit cannot currently be calculated for Cantabio Pharmaceuticals.

What is the business model of Cantabio Pharmaceuticals

Cantabio Pharmaceuticals Inc. is a biotechnology company specializing in the discovery and development of novel therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company combines modern science, artificial intelligence, and big data analytics to develop effective drugs that target the underlying pathology and can slow down disease progression. Cantabio Pharmaceuticals has three main segments: Research and Development, Business Development, and Investor Relations. The company has multiple promising drugs in its pipeline, including CB2817 for Alzheimer's treatment. Cantabio Pharmaceuticals is focused on the discovery and development of innovative therapies for neurodegenerative diseases, and is well-positioned in the field of neuroscience.

What is the Cantabio Pharmaceuticals dividend?

Cantabio Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Cantabio Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Cantabio Pharmaceuticals or the company does not pay out a dividend.

What is the Cantabio Pharmaceuticals ISIN?

The ISIN of Cantabio Pharmaceuticals is US13808X2036.

What is the Cantabio Pharmaceuticals WKN?

The WKN of Cantabio Pharmaceuticals is A2PMPJ.

What is the Cantabio Pharmaceuticals ticker?

The ticker of Cantabio Pharmaceuticals is CTBO.

How much dividend does Cantabio Pharmaceuticals pay?

Over the past 12 months, Cantabio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cantabio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cantabio Pharmaceuticals?

The current dividend yield of Cantabio Pharmaceuticals is .

When does Cantabio Pharmaceuticals pay dividends?

Cantabio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cantabio Pharmaceuticals?

Cantabio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cantabio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cantabio Pharmaceuticals located?

Cantabio Pharmaceuticals is assigned to the '-' sector.

Wann musste ich die Aktien von Cantabio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cantabio Pharmaceuticals from 7/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/24/2024.

When did Cantabio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/24/2024.

What was the dividend of Cantabio Pharmaceuticals in the year 2023?

In the year 2023, Cantabio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cantabio Pharmaceuticals pay out the dividend?

The dividends of Cantabio Pharmaceuticals are distributed in USD.

All fundamentals about Cantabio Pharmaceuticals

Our stock analysis for Cantabio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cantabio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.